ESSA Pharma shares are trading higher after the company announced it presented data on prostate cancer therapy Masofaniten at ESMO 2024.
Portfolio Pulse from Benzinga Newsdesk
ESSA Pharma's shares rose following the presentation of data on its prostate cancer therapy, Masofaniten, at ESMO 2024.
September 16, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ESSA Pharma's stock price increased after the company presented new data on its prostate cancer therapy, Masofaniten, at the ESMO 2024 conference.
The presentation of new data on Masofaniten, a prostate cancer therapy, at a major conference like ESMO 2024 is likely to boost investor confidence in ESSA Pharma's product pipeline, leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100